Cerenome, Inc. (NASDAQ:CNSY) has presented interim clinical data from its ongoing ReSPECT-LM study evaluating repeated intraventricular administration of REYOBIQ (rhenium Re186 obisbemeda) in patients with leptomeningeal metastases, a form of cancer involving the membranes surrounding the brain and spinal cord.
The findings, covering the first 10 patients treated in the study, were presented at the Society for Neuro-Oncology’s 31st Annual Meeting in Philadelphia on November 13, 2026.
According to the company, no dose-limiting toxicities or adverse events resulting in treatment discontinuation were observed among the patients included in the interim analysis.
The company also reported preliminary observations relating to disease progression, radiation exposure and changes in tumour-cell levels in cerebrospinal fluid.
REYOBIQ remains an investigational treatment and has not received approval from the US Food and Drug Administration for any indication.
ReSPECT-LM Study Evaluates Repeated Intraventricular Administration
The ReSPECT-LM study is investigating the safety and clinical characteristics of administering REYOBIQ repeatedly into the brain’s ventricular system.
The interim analysis included 10 patients with leptomeningeal metastases arising from several different primary cancers.
These included melanoma, breast cancer, non-small cell lung cancer, ovarian cancer and neuroendocrine cancer.
Nine of the 10 participants had previously received treatment for leptomeningeal metastases.
Six patients received REYOBIQ at an administered activity of 13.2 millicuries (mCi) per treatment, while four received 26.4 mCi per administration.
The study is assessing the tolerability of repeated dosing, alongside measurements of radiation exposure and preliminary indicators of clinical activity.
Repeat Dosing Reaches Cumulative Activity of 79.2 mCi
Cerenome highlighted dosing information from one patient who completed three administrations of REYOBIQ at 26.4 mCi per treatment.
The patient received a cumulative administered activity of 79.2 mCi, exceeding the highest single-dose activity of 75 mCi evaluated in the earlier single-dose study.
The estimated cumulative absorbed radiation dose to the leptomeningeal compartment was 207 gray (Gy).
No dose-limiting toxicities were reported in this patient.
The company also assessed consistency in absorbed radiation doses across repeated administrations.
The median within-patient coefficient of variation in absorbed dose per administration was 8%, indicating relatively limited variation between administrations in the measurements reported.
These observations provide preliminary information about repeated administration and radiation distribution, although the analysis is based on a small number of patients.
No Disease Progression Recorded at Three- and Six-Month Assessments
The interim analysis included preliminary observations of leptomeningeal metastases progression at specified follow-up intervals.
At the three-month assessment, none of the five evaluable patients had documented disease progression.
The same result was reported at six months, with no progression recorded among five evaluable patients.
At nine months, progression was documented in one of four evaluable patients.
The findings reflect the patients with available assessments at each time point and do not represent progression outcomes for all 10 participants.
Because the study remains ongoing and the interim analysis involves a limited patient population, the results cannot establish the treatment’s efficacy or determine how outcomes compare with other therapies.
Safety Findings Include Nausea, Headache and Reduced Blood Cell Counts
Cerenome reported that no dose-limiting toxicities had occurred among the first 10 patients included in the analysis.
No adverse events resulted in discontinuation of treatment.
The most frequently reported treatment-emergent adverse events were nausea, affecting 60% of patients, and headache, reported in 40%.
Decreased lymphocyte counts and decreased white blood cell counts were each observed in 40% of participants.
The company did not provide a detailed breakdown of adverse event severity in the interim information.
Further safety monitoring will be required as additional patients receive treatment and longer-term follow-up data become available.
CNSide Monitoring Identifies Reductions in Cerebrospinal Fluid Tumour Cells
The study also incorporated serial cerebrospinal fluid monitoring using Cerenome’s CNSide platform.
The technology was used to assess changes in tumour-cell levels during treatment.
According to the company, individual patients demonstrated reductions in detectable tumour cells over the course of monitoring.
Three patients who had measurable tumour cells in their cerebrospinal fluid at baseline subsequently recorded levels of zero tumour cells per millilitre.
These findings represent exploratory observations from individual patients rather than confirmed evidence of a clinical benefit across the study population.
The company did not provide sufficient information to determine how long the observed reductions were maintained or whether they were associated with improvements in survival.
Phase 2 Randomised Study Targeted for 2027
Cerenome said it is targeting the initiation of a Phase 2 randomised clinical study of REYOBIQ in 2027.
The proposed next stage remains dependent on continued clinical progress and alignment with regulatory authorities.
The ongoing ReSPECT-LM programme is supported by a $17.6 million grant from the Cancer Prevention & Research Institute of Texas.
The interim findings provide initial information about the safety, dosing characteristics and preliminary clinical observations associated with repeated REYOBIQ administration.
However, the treatment remains investigational, and additional clinical data will be needed to evaluate its efficacy and safety in a larger patient population.
